Outcomes of imatinib and allogeneic hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia / 中华血液学杂志
Chinese Journal of Hematology
;
(12): 126-128, 2014.
Article
in Chinese
| WPRIM
| ID: wpr-295695
ABSTRACT
<p><b>OBJECTIVE</b>To compare the curative effect of imatinib and allogeneic hematopoietic stem cell transplant (allo-HSCT) in the treatment of chronic myeloid leukemia (CML).</p><p><b>METHODS</b>292 CML patients received imatinib, and 141 patients underwent allo-HSCT. The clinical data of these patients were retrospectively analyzed to compare event- free survival (EFS) and overall survival (OS) between these two groups of patients in chronic and advanced (including accelerate and blast) phases.</p><p><b>RESULTS</b>(1) EFS, OS, expected 5- year EFS and OS of imatinib group (278 patients in chronic phase) were all statistically higher than of allo-HSCT group (120 patients in chronic phase) (88.5% vs 70.0%, 93.2% vs 80.0%, 84.0% vs 75.0% and 92.0% vs 79.0%, respectively, all P values < 0.01). (2) EFS and OS of imatinib group (14 patients in accelerate and blast phases) were 42.9% and 42.9%, respectively. Meanwhile EFS and OS of allo-HSCT group (21 patients in accelerate and blast phases) were 47.6% and 57.1%, respectively. There were no significant differences in terms of EFS and OS between the two groups (P values>0.05).</p><p><b>CONCLUSION</b>EFS and OS of imatinib group were significantly higher than of allo-HSCT group for CML patients of in chronic phase. Imatinib and allo-HSCT had the similar efficacy for CML patients in accelerate and blast phases.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Piperazines
/
Pyrimidines
/
Therapeutics
/
Transplantation, Homologous
/
Benzamides
/
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Retrospective Studies
/
Hematopoietic Stem Cell Transplantation
/
Disease-Free Survival
/
Therapeutic Uses
Type of study:
Observational study
Limits:
Adolescent
/
Adult
/
Aged
/
Child
/
Child, preschool
/
Female
/
Humans
/
Male
Language:
Chinese
Journal:
Chinese Journal of Hematology
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS